Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow AIM ImmunoTech Inc.

Get SEC filing alerts via email and in your feed for AIM ImmunoTech Inc.

AIM AIMI

AIM ImmunoTech Inc.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company based in Ocala, Florida, focused on developing therapeutics for cancer, viral diseases, and immune disorders. Its flagship products, Ampligen and Alferon N Injection, target unmet medical needs. AIM is exploring Ampligen's potential in pancreatic cancer and as an antiviral treatment, including for COVID-19. The company is actively conducting clinical trials and seeking FDA approval to expand its market presence.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from AIM ImmunoTech Inc.

1
1
AIM ImmunoTech Inc. AIM ImmunoTech Reports $3M Net Loss and 37.5% Revenue Increase for Q1 2026

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
AIM ImmunoTech Inc. AIM ImmunoTech Reports $13.96 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
AIM ImmunoTech Inc. AIM ImmunoTech Reports $3.3 Million Net Loss in Q3 2025, Improved from Previous Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
AIM ImmunoTech Inc. AIM ImmunoTech Reports Increased Net Loss and Decreased Revenues for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
AIM ImmunoTech Inc. AIM ImmunoTech Reports $3.7 Million Net Loss for Q1 2025, Seeks Additional Funding

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
AIM ImmunoTech Inc. AIM ImmunoTech Reports $17.3 Million Net Loss for Fiscal Year 2024, Focuses on Ampligen Development

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
AIM ImmunoTech Inc. Aim ImmunoTech Reports Decline in Revenues, Reduction in Losses for Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments